Predictors of preclinical Alzheimer disease and dementia: A clinicopathologic study

Archives of Neurology

Volumn 62, Issue 5, 2005, Pages 758-765

  Galvin, James E ^a,d   Powlishta, Kimberly K ^a,b   Wilkins, Kenneth ^a,c   McKeel Jr , Daniel W ^a   Xiong, Chengjie ^a   Grant, Elizabeth ^a   Storandt, Martha ^a   Morris, John C ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN INFARCTION; CLINICAL DEMENTIA RATING; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DEPRESSION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTELLIGENCE TEST; LEWY BODY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOLOGIC TEST; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; RATING SCALE; UNITED STATES;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; APOLIPOPROTEINS E; AUTOPSY; DEMENTIA; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY; MENTAL STATUS SCHEDULE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PSYCHOMETRICS; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 18544367850     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.5.758     Document Type: Article

References (31)

1. Sliwinski M, Lipton RB, Buschke H, Stewart W. The effects of preclinical dementia on estimates of normal cognitive functioning in aging. J Gerontol B Psychol Sci Soc Sci. 1996;51:P217-P225.
2. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologie markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55: 326-335.
3. Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998;55: 395-401.
4. Morris JC, McKeel DW, Storandt M, et al. Very mild Alzheimer's disease: informant-based clinical, psychometric and pathologic distinction from normal aging. Neurology. 1991;41:469-478.
5. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
6. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46:661-665.
7. Wilson RS, Beckett LA, Bennett DA, Albert MS, Evans DA. Change in cognitive function in older persons from a community population. Arch Neurol. 1999; 56:1274-1279.
8. Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001; 56:49-56.
9. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
10. McKeel DW Jr, Price JL, Miller JP, et al. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of the Alzheimer type. J Neuropathol Exp Neurol. 2004;63:1028-1037.
11. McKeel DW Jr, Ball MJ, Price JL, et al. Interlaboratory histopathologic assessment of Alzheimer's neuropathology: different methodologies yield comparable diagnostic results. Alzheimer Dis Assoc Disord. 1993;7:136-151.
12. Goldman WP, Price JL, Storandt M, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001;56:361-367.
13. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive status of patients for the clinicians. J Psychiatr Res. 1975; 12:189-198.
14. Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140:734-739.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
16. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
17. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;49:1113-1124.
18. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREM International Workshop. Neurology. 1993;43:250-260.
19. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
20. Davis PB, White H, Price JL, McKeel D, Robins LN. Retrospective postmortem dementia assessment: validation of a new clinical interview to assist neuropathologic study. Arch Neurol. 1991;48:613-617.
21. Storandt M, Hill RD. Very mild senile dementia of the Alzheimer type, II: psychometric test performance. Arch Neurol. 1989;46:383-386.
22. National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18:S1-S2.
23. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3-12.
24. Kanne SM, Balota DA, Storandt M, McKeel DW Jr, Morris JC. Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later. Neurology. 1998;50:979-985.
25. Braak H, Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm. 1998;105:801-819.
26. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer's disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998; 57:1168-1174.
27. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000;55:370-376.
28. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
29. Wilson RS, Barnes LL, de Leon M, et al. Depressive symptoms, cognitive decline and risk of AD in older persons. Neurology. 2002;59:364-370.
30. Berger AK, Fratiglioni L, Forsell Y, Winblad B, Backman L. The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology. 1999;53:1998-2002.
31. Rubin EH, Veiel LL, Kinscherf DA, Morris JC, Storandt M. Clinically significant depressive symptoms and very mild to mild dementia of the Alzheimer type. Int J Geriatr Psychiatry. 2001;16:694-701.